Wed Sep 04 2024
The use of mRNA as a vaccine platform has been mostly derisked and its speed to move from antigen discovery to drug product is impressive. However, high-purity mRNA can still be a challenge to make. Dr. Christian Cobaugh, CEO of Vernal Biosciences, is on a mission to make high-purity mRNA available to more researchers and drug developers to help realize even more potential from mRNA medicines.
Get AI-powered summaries and transcripts for any meeting, phone call, or podcast.
Available on iOS, Android, Mac, and Windows
No transcript available.
